MBX — MBX Biosciences, Inc. Common Stock

Founder-Led

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

Trend Edge Setup Score

Trend Edge rates MBX Bullish with a Setup Score of 34, net conviction 35, actionability 34. How the Setup Score works →

Total Setup Score34
Directional BiasBullish
Net Conviction35
Actionability34 (in range)

Key signals behind this score

About MBX Biosciences, Inc. Common Stock

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$49.55
Market Cap$2.65B
Float31.2M
Shares Outstanding49.7M
vs. Analyst Target+91.9% to analyst PT
Dividend RateNone
Analyst Target Price$95.09 (12 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2022 N/A -$26.1M -$56,000 -$25.7M
2023 N/A -$32.6M -$157,000 -$32.4M
2024 N/A -$61.9M -$244,000 -$61.7M
2025 N/A -$87.0M -$248,000 -$86.7M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Dec 2025 N/A -$22.1M
Mar 2026 N/A -$23.5M
Jun 2026 N/A -$37.1M
Sep 2026 N/A -$62.4M

Ownership & Float

Insider Ownership2.8%
Institutional Ownership113.1%
Short Float13.4%
% of All Funds Holding2.16%
Number of Funds Holding190

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$53.91Near-term / short-term trend
Weekly40-Week SMA$46.89Medium-term trend
Weekly80-Week SMA$33.72Cyclical trend (business cycle)
Weekly200-Week SMA$0.00Secular trend (multi-year)
Monthly10-Month SMA$47.09Near-term monthly trend
Monthly20-Month SMA$33.79Medium-term monthly trend
Monthly40-Month SMA$0.00Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$30.30 support 1.14x 4 months ago
$18.20 support 1.80x 12 months ago

Historical Earnings Reactions (9 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap -0.87% 0.54% 66.67% 3.84% -11.44%
1 Day 2.85% 1.06% 55.56% 18.02% -7.81%
1 Week -0.23% 0.20% 55.56% 32.21% -27.81%
2 Weeks -0.91% -1.46% 37.50% 28.75% -26.37%
1 Month -5.84% -6.58% 25.00% 16.49% -33.90%

Next earnings: January 28, 2027 (66 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.65% 47.2% 106
Tuesday 0.12% 53.1% 113
Wednesday 1.23% 58.6% 111
Thursday -0.22% 50.5% 107
Friday -0.05% 47.2% 108

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 113.1%

Insider Transactions — Smart Summary

Total insider ownership: 2.8%

Founder-led management: Kent Hawryluk (President, Chief Executive Officer, and Director)

12-Month Insider Activity Summary

Total Filings7
Net Value-$1.7M
Net Shares Change12,026
% of Float0.0%
C-Suite Filings7
Clusters Detected0

Key Insiders

NameTitleNet ValueFilingsActivity
Azoulay Salomon Chief Medical Officer -$1.9M 4 3 sell
Hawryluk P. Kent President & CEO +$507,731.92 2 1 buy, 1 sell
Hoerter Steven L. Chairman, President and CEO -$268,234.26 1 1 sell

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-11-12 Hoerter Steven L. Chairman, President and CEO -$268,234.26 Transaction at $54.82, now -9.6%
2026-11-05 Azoulay Salomon Chief Medical Officer -$20,127.08 Transaction at $53.96, now -8.2%
2026-03-16 Hawryluk P. Kent President & CEO +$525,662.7 Transaction at $28.41, now +74.4%
2026-08-05 Azoulay Salomon Chief Medical Officer -$24,334.9 Transaction at $65.77, now -24.7%
2026-05-08 Hawryluk P. Kent President & CEO -$17,930.78 Transaction at $29.54, now +67.7%
2026-05-08 Azoulay Salomon Chief Medical Officer -$6,823.74 Transaction at $29.54, now +67.7%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for MBX Biosciences, Inc. Common Stock (MBX) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for MBX on Trend Edge →